This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Vanda Pharmaceuticals (VNDA) Earnings Expected to Grow: What to Know Ahead of Q3 Release
by Zacks Equity Research
Vanda (VNDA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Vanda (VNDA) Upgraded to Buy: Here's Why
by Zacks Equity Research
Vanda (VNDA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Vanda (VNDA) Loses 21.1% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
by Zacks Equity Research
Vanda (VNDA) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Allogene (ALLO) Q2 Earnings Top, Sales Lag, Pipeline Advances
by Zacks Equity Research
Allogene (ALLO) beats earnings estimates but misses the same for revenues in the second quarter.
Sarepta (SRPT) Q2 Earnings Beat, 2021 Sales View Raised
by Zacks Equity Research
Strong demand for Sarepta's (SRPT) DMD drugs boosts its top line in Q2. The company also raises revenues guidance for the year. It plans to start a pivotal study on SRP-9001 next month. Stock up.
Deciphera (DCPH) Q2 Loss Wider Than Expected, Revenues Beat
by Zacks Equity Research
Deciphera (DCPH) posts wider-than-expected loss in the second quarter due to rising R&D costs. Sales beat estimates on the encouraging uptake of Qinlock.
Ultragenyx (RARE) Q2 Loss Widens Y/Y, Revenues Beat Estimates
by Zacks Equity Research
Ultragenyx Pharmaceutical's (RARE) Q2 sales increase year over year while loss widens.
Agios' (AGIO) Q2 Loss Narrows, Pipeline Makes Solid Progress
by Zacks Equity Research
Agios Pharmaceuticals (AGIO) reports narrowed-than-expected loss for the second quarter of 2021. The company did not record any revenue following the oncology portfolio sale.
Vanda (VNDA) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Vanda (VNDA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Blueprint Medicines (BPMC) Misses on Q2 Earnings & Revenues
by Zacks Equity Research
Blueprint Medicines (BPMC) misses estimates for revenues and earnings in the second quarter of 2021. Nevertheless, the company provides encouraging pipeline updates.
Vanda Pharmaceuticals (VNDA) Matches Q2 Earnings Estimates
by Zacks Equity Research
Vanda (VNDA) delivered earnings and revenue surprises of 0.00% and -4.37%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Vanda (VNDA) Moves 5.8% Higher: Will This Strength Last?
by Zacks Equity Research
Vanda (VNDA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Find Great Stocks with this New Analyst Coverage Screener
by Benjamin Rains
One way to find potential winners is to search for companies that have landed new analyst coverage recently. And the reasoning is pretty straightforward...
Vanda Pharmaceuticals (VNDA) Surpasses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Vanda (VNDA) delivered earnings and revenue surprises of 7.14% and 166.68%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Vanda Pharmaceuticals (VNDA) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Vanda (VNDA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BioCryst (BCRX) Wins FDA Approval for HAE Drug Orladeyo
by Zacks Equity Research
BioCryst (BCRX) obtains FDA approval for berotralstat for prophylaxis to prevent attacks of hereditary angioedema in adults and pediatric patients.
Rhythm (RYTM) Up on FDA Approval of Weight Management Drug
by Zacks Equity Research
Rhythm's (RYTM) stock gains as FDA approves its lead product candidate for chronic weight management.
Alexion's (ALXN) Ultomiris IV Formulation Gets EC Approval
by Zacks Equity Research
Alexion's (ALXN) new 100 mg/mL intravenous (IV) formulation of Ultomiris gets EC approval for PNH and aHUS.
Roche (RHHBY) Gets FDA Nod for Influenza Drug Label Expansion
by Zacks Equity Research
Roche (RHHBY) gets FDA approval for Xofluza to prevent influenza in people 12 years of age and older following contact with someone with influenza.
Bristol Myers' (BMY) CAR T-Cell Therapy BLA Review Delayed
by Zacks Equity Research
Bristol Myers (BMY) announces a delay in the FDA review of its BLA for lisocabtagene maraleucel due to COVID-19 pandemic.
Roche's (RHHBY) Influenza Drug Gets Positive CHMP Opinion
by Zacks Equity Research
Roche's (RHHBY) influenza drug Xofluza and Phesgo (fixed-dose combination of Perjeta and Herceptin for subcutaneous injection) get a positive CHMP opinion.
Vanda Pharmaceuticals (VNDA) Q3 Earnings Surpass Estimates
by Zacks Equity Research
Vanda (VNDA) delivered earnings and revenue surprises of 37.50% and -5.77%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Vanda Pharmaceuticals (VNDA) Q2 Earnings Surpass Estimates
by Zacks Equity Research
Vanda (VNDA) delivered earnings and revenue surprises of 100.00% and -1.26%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Vanda Pharmaceuticals (VNDA) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Vanda (VNDA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
FDA Grants Extra Access to Vanda's Tradipitant to a Patient
by Zacks Equity Research
Vanda (VNDA) gets authorization from the FDA for expanded access to tradipitant for a single patient for six more months.